Brighthouse Financial, Inc. (BHF): what the price requires

At today's price, Brighthouse Financial, Inc. (BHF) is priced for 9.7% return on equity. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/BHF

Headline

FieldValue
TickerBHF
CompanyBrighthouse Financial, Inc.
Current price$66.62/sh
CompositionAnnuities 60% / Life 19% / Run-off 21%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Return on equity needed9.7%
Return on equity now4.9%
ROE gap+4.8pp
Price-to-book0.69x

Solve inputs: computed at a 12.3% cost of equity with 4% terminal growth over a 5-year stage, on common book equity (FY2026); each 1pp of cost of equity moves the implied ROE ~0.7pp.

Reconcile: at the x-ray's 9.3% required return this reads ~7.6%; the models below use their own rates.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.77σ
cohort percentile (of 80 peers)5
sustained it ~10 years at this level77%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and relative-multiple value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset0.72x2justifies
Earnings—0—
Relative0.54x1justifies
Growth—0—

Families that justify the price: Asset, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.8%); the inversion above states its own rate.

Per-Model Detail (n=3)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)———no—
Relative ValuationRelative$123.560.54xyesP/S fallback (negative EPS): Sector P/S 1.2x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$97.030.69xyesReference only (book value floor): BV/sh $97.03, ROE negative
Two-Stage Excess ReturnAsset$87.330.76xyesReference only (book value with convergence): BV/sh $97.03, ROE converges to ke
Discounted Future Market CapGrowth$29.452.26xnoRev $5.9B, growth -11% (input: historical growth; tapered), Terminal P/S: 0.5x / 0.6x / 0.7x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (buyback)-7.3%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

The stage this company is in changes how every number should be read. Brighthouse is not a going concern to be valued on growth or even on book value in the usual way. It is a company that has agreed to sell itself. Stockholders approved an all-cash acquisition by Aquarian Capital at $70.00 a share on February 12, 2026, with roughly 99.7% of votes cast in favor. At $62.26, the stock trades below that contracted price. So the bull case is unusually concrete: the upside is the difference between today's price and a fixed cash number, realized when the deal closes, rather than a thesis about future returns on equity. The investor is underwriting the completion of a transaction, not the long-run economics of selling annuities.

The reason a buyer wanted the company in the first place is the same reason the standalone valuation looks cheap. Brighthouse carries a tangible book value near $117.68 per share, and the price sits at roughly half of that, a price-to-book around 0.53. An acquirer paying $70.00 in cash is still buying the franchise well below tangible book. The capital position supports the deal: the risk-based capital ratio has run in the 430% to 450% range, far above regulatory minimums, which is precisely the kind of overcapitalized balance sheet a private acquirer can put to work. The annuities engine remains the cash producer underneath: 2025 set records with $10.3 billion of annuity sales, and adjusted earnings in the Annuities segment held steady, $324 million in the first quarter of 2026 against $314 million a year earlier.

Capital return has been the standalone story for years, and it remains the floor if the deal somehow falls through. The share count has fallen roughly 8.8% a year, an aggressive buyback program that retired stock at a steep discount to book and is direct evidence of how undervalued management considered its own equity. That is the bull's safety net: a buyer has put a $70.00 cash price on the table, the company trades below it, and the underlying business is an overcapitalized insurer that was repurchasing its own shares well under tangible book. The bet is that the regulators clear the transaction.

Bear Case

The variable with the most leverage on this thesis is not market or interest-rate risk. It is regulatory approval, and the current price reflects that the market is not certain it comes. The acquisition by Aquarian Capital still requires sign-off from state insurance regulators in Texas, Delaware, New York, and Massachusetts. Insurance regulators exist to protect policyholders, and a private-capital buyer taking control of a life-and-annuity insurer with long-dated obligations is exactly the kind of transaction they scrutinize hardest. The roughly 12% gap between the $62.26 price and the $70.00 cash terms is the market quoting real completion risk. If any of those four regulators balk, or attach conditions the buyer will not accept, the deal does not close at $70.00, and the spread that looks like upside becomes the warning it was.

What makes a break especially painful is where the stock lands if the deal fails. Brighthouse on its own is a deeply troubled standalone story. The first quarter of 2026 produced a net loss available to shareholders of $792 million, or $13.82 per diluted share. That figure reflects the violent way market and hedging movements run through a variable-annuity insurer's GAAP earnings, but it is also why the company trades at half of tangible book in the first place: the market does not trust the reported book to convert into shareholder value. The return on equity sits near 4.9%, well below the cost of equity the market demands of a business with this earnings volatility. A standalone Brighthouse is a company the market valued at roughly half its stated book for reasons that predate the deal.

So the bear case is a binary. If the regulators approve, the holder collects $70.00 and the standalone problems never matter. If they do not, the support under the price is a franchise the market already discounted by half, with earnings that can swing to a multi-hundred-million-dollar quarterly loss on market moves outside management's control. The standard solvency lenses do not apply to an insurer of this kind: the relevant frame is regulatory capital, and there the picture is genuinely strong, with a risk-based capital ratio in the 430% to 450% range. But strong regulatory capital is what makes the company an attractive acquisition; it does not protect the share price if the acquisition is the thing that breaks. The bear is not that the business is insolvent. It is that the price has detached from the standalone business and reattached to a deal that four regulators still have to bless.

Valuation

The cleanest way to value Brighthouse today is to recognize that the market already has, twice, and the two answers disagree. There is the deal price, $70.00 a share in cash from Aquarian Capital, fixed and contracted. And there is the standalone price the stock would find without the deal, which the valuation methods peg far higher than where it trades on paper but which the market clearly does not trust. At $62.26, the stock sits between a contracted exit and a discounted standalone, and the distance from $62.26 to $70.00 is the market's estimate of completion risk, not a valuation gap.

On the standalone math, every lens says cheap, and that is the point rather than a recommendation. The price sits below where the asset-value methods land, below the peer-multiple read, below the earnings-power read. A book-value-plus-profitability frame for an insurer lands near $58.84, close to the price, because it correctly penalizes a return on equity of about 4.9% against the cost of equity the market demands. But the tangible book value itself is $117.68 per share, so the stock trades at roughly 0.53 times book. The reason a half-of-book insurer is not an obvious bargain is volatility: the first quarter of 2026 swung to a $792 million net loss on market and hedging movements, the kind of earnings instability that justifies the market's discount to stated book. The deep discount is real; so is the reason for it.

For an insurer, the solvency frame is regulatory capital and payout capacity, not corporate leverage or cash burn, and on that measure Brighthouse is strong: a risk-based capital ratio running 430% to 450%. That strength is exactly what made the company a target, and it is what would underpin the price if the deal broke. The decisive number, though, is not any model output. It is the $70.00 cash price against the $62.26 quote: what the investor is actually underwriting at this price is a regulatory approval, with a deeply discounted standalone insurer as the fallback if it does not come.

Catalysts

The dominant catalyst is the merger itself, and its timeline now drives the stock. Aquarian Capital agreed to acquire Brighthouse in an all-cash deal valued at roughly $4.1 billion, $70.00 per share, and stockholders ratified it on February 12, 2026, with about 99.7% of votes cast in favor and roughly 69.7% of outstanding shares represented. The remaining gate is regulatory: filings have gone to state insurance regulators in Texas, Delaware, New York, and Massachusetts, and the company expects the transaction to close sometime in 2026, subject to those approvals and customary closing conditions. Each regulatory milestone is a price event, because the spread between today's quote and $70.00 narrows as approval risk falls and widens if any approval stalls.

The underlying business results matter mainly as the fallback case if the deal does not close. The first quarter of 2026 showed the split-screen typical of a variable-annuity insurer: a GAAP net loss available to shareholders of $792 million, or $13.82 per diluted share, alongside positive adjusted earnings of $251 million, with the Annuities segment contributing adjusted earnings of $324 million. Annuity sales were $2.2 billion in the quarter, down from the record pace of 2025, which delivered $10.3 billion of annuity sales for the full year. The next concrete catalysts are the state regulatory decisions; until those resolve, the operating prints move the standalone fallback value, not the deal price the stock is anchored to.

Peer Cohorts (Per Segment, With Filing Citations)

Annuities (reported)

Life (reported)

Run-off (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Brighthouse Financial merger vote disclosure, February 2026 · Aquarian merger filings, 2026 · company financial disclosures, 2026 · Brighthouse Financial capital disclosures, 2026 · Brighthouse Financial Q1 2026 results, May 2026 · Brighthouse Financial merger disclosures, 2026 · Brighthouse Financial results, 2025-2026

View the full interactive BHF report on boothcheck